Immunohistochemical neuroendocrine marker expression in primary pulmonary NUT carcinoma: a diagnostic pitfall

2020 ◽  
Vol 77 (3) ◽  
pp. 508-510
Author(s):  
Federica Pezzuto ◽  
Francesco Fortarezza ◽  
Marco Mammana ◽  
Giulia Pasello ◽  
Giuseppe Pelosi ◽  
...  
Keyword(s):  
Neuroendocrine Marker ◽  
Diagnostic Pitfall ◽  
Marker Expression ◽  
Nut Carcinoma

scholarly journals The Isoform Matters in NUT Carcinoma: A Diagnostic Pitfall of p40 Immunohistochemistry

2020 ◽  
Vol 15 (10) ◽  
pp. e176-e178 ◽  
Author(s):  
Kohei Matsuda ◽  
Jumpei Kashima ◽  
Yasushi Yatabe
Keyword(s):  
Diagnostic Pitfall ◽  
Nut Carcinoma

scholarly journals Composite hemangioendothelioma with neuroendocrine marker expression: an aggressive variant

2017 ◽  
Vol 30 (11) ◽  
pp. 1589-1602 ◽  
Author(s):  
Kyle D Perry ◽  
Alyaa Al-lbraheemi ◽  
Brian P Rubin ◽  
Jin Jen ◽  
Hongzheng Ren ◽  
...  
Keyword(s):  
Neuroendocrine Marker ◽  
Marker Expression ◽  
Aggressive Variant

Oestradiol Induced Inhibition of Neuroendocrine Marker Expression in Leydig Cells of Adult Rats

2006 ◽  
Vol 41 (3) ◽  
pp. 204-209 ◽  
Author(s):  
HH Ortega ◽  
NR Salvetti ◽  
C Baravalle ◽  
JA Lorente ◽  
GA Mira
Keyword(s):  
Leydig Cells ◽  
Adult Rats ◽  
Neuroendocrine Marker ◽  
Marker Expression

scholarly journals Erratum: Composite hemangioendothelioma with neuroendocrine marker expression: an aggressive variant

2017 ◽  
Vol 30 (10) ◽  
pp. 1512-1512 ◽  
Author(s):  
Kyle D Perry ◽  
Alyaa Al-lbraheemi ◽  
Brian P Rubin ◽  
Jin Jen ◽  
Hongzheng Ren ◽  
...  
Keyword(s):  
Neuroendocrine Marker ◽  
Marker Expression ◽  
Aggressive Variant

scholarly journals Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Yan Wu ◽  
Yumei Lai ◽  
Miao Zhang ◽  
Zhongwu Li
Keyword(s):  
Cox Regression ◽  
Prognostic Significance ◽  
Progression Free Survival ◽  
Aberrant Expression ◽  
Neuroendocrine Marker ◽  
Neuroendocrine Markers ◽  
Immunohistochemical Markers ◽  
Kaplan Meier ◽  
Marker Expression ◽  
Weak Expression

Abstract Background Melanoma is a highly malignant tumor with diverse histopathological morphology and frequent aberrant expression of immunohistochemical markers. An occasionally reported phenomenon is the abnormal expression of neuroendocrine markers. Awareness of this situation is essential because such tumors need to be differentiated from neuroendocrine tumors because of their significant therapeutic and prognostic implications. Methods We retrospectively analyzed the expression of chromogranin A (CgA), synaptophysin (Syn) and CD56 as neuroendocrine markers in 308 cases with melanomas. Kaplan-Meier curves and Cox regression analyses were used for overall survival (OS) and progression-free survival (PFS) evaluation and comparison between neuroendocrine markers expression status in all melanoma cases or stage I–II cases. Results The expression of neuroendocrine markers in melanomas is not uncommon. CgA was positive in 6/304 (2.0%) cases, Syn in 26/304 (8.6%), and CD56 in 56/189 (29.6%). None of the cases co-expressed all the three markers. Focal or weak expression of at least one neuroendocrine marker was identified in 70/188 (37.2%) cases. The expression of CgA was correlated with age (p = 0.019), while the positive expression of Syn and CD56 showed borderline significance (p = 0.078 and 0.083, respectively), but not for any neuroendocrine marker expression. The expression of any neuroendocrine marker showed borderline significance with staging (p = 0.066). The expression of CgA, Syn, CD56, or any neuroendocrine marker did not correlate with clinicopathological features including sex, specimen type, origin, location, and histology subtype. Survival analyses revealed that the expression of neuroendocrine markers was not associated with OS or PFS. Conclusions Our study confirms that neuroendocrine marker expression is a common phenomenon in melanomas, but it has no prognostic significance. Nevertheless, awareness can avoid misdiagnosis in cases of melanomas with unusual morphology and immunophenotypes.

scholarly journals Thoracic composite hemangioendothelioma with neuroendocrine marker expression

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Ei Miyamoto ◽  
Kenji Seki ◽  
Hiroyuki Katsuragawa ◽  
Yuji Yoshimoto ◽  
Yuki Ohsumi ◽  
...  
Keyword(s):  
Chest Wall ◽  
Spinal Canal ◽  
Soft Tissues ◽  
En Bloc Resection ◽  
Bloc Resection ◽  
En Bloc ◽  
Tissue Mass ◽  
Neuroendocrine Marker ◽  
Marker Expression ◽  
The Right

Abstract Background Composite hemangioendothelioma is an extraordinarily rare form of vascular neoplasm which develops predominantly in the skins and soft tissues of the adults. Neuroendocrine marker expression in composite hemangioendothelioma is considered as specifically relevant to the more aggressive behavior. Case presentation The patient was a 71-year-old man complaining continuous back pain. Computed tomography (CT) showed that 10 cm of contrast-enhanced soft tissue mass was occurring on the right posterior chest wall and developing adjacent to the spinal canal. Via the laminectomy, the tumor end was identified and separated from the dura mater. Then, via the posterolateral thoracotomy, the en bloc resection was achieved by separating the tumor from the diaphragm and vertebras. Histologic examination showed a complex combination of epithelioid and retiform hemangioendothelioma areas which were positive for anti-synaptophysin staining. At 12-month follow-up, there were no signs of tumor recurrence on CT, and the patient had no symptom. Conclusions We achieved the complete resection of a huge thoracic neuroendocrine composite hemangioendothelioma developing adjacent to the spinal canal. The combination of the posterior lumbar laminectomy and the following posterior thoracotomy is a viable approach to radically resect a thoracic neuroendocrine composite hemangioendothelioma involving chest wall.

Sign in / Sign up

Export Citation Format

Share Document